Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment for the Symplicity™ blood pressure procedure, increasing access to care for patients with uncontrolled hypertension.

Effective January 1, 2025 



This is the turning point in hypertension care.

Current hypertension care strategies are not aIways enough to help patients achieve blood pressure control. The Symplicity™ procedure is the only interventional approach using a single catheter and radiofrequency (RF) energy to help lower blood pressure. 


75% of hypertension patients in the United States do not have their blood pressure under control,1 yet reducing blood pressure can significantly impact risk for cardiovascular events.

A 10 mmHg reduction in office systolic blood pressure decreases risk for2:

  • Major CV events by 20%
  • Stroke by 27%
  • Heart failure by 28%
     



Evidence showing safety and efficacy

The Symplicity Spyral™ renal denervation system is proven to achieve significant, safe, and sustained blood pressure reductions in the presence and absence of medications in multiple clinical trials and a real-world patient registry.3–6


Results may vary.




How the system works

The Symplicity Spyral™ system is comprised of the Symplicity Spyral™ multi-electrode renal denervation catheter and the Symplicity G3™ renal denervation RF generator.

Patients whose blood pressure is difficult to control may have an overactive sympathetic nervous system. The Symplicity™ procedure aims to suppress this inappropriately elevated sympathetic drive. The Symplicity Spyral™ system offers a versatile, simple, and minimally invasive method to perform renal denervation.§,7

The procedure is performed by interventionalists due to its similarity to other procedures they perform every day.




Patient selection considerations

Understanding which patients could benefit from the Symplicity™ procedure is an important step when considering this therapy. 

Your patients may benefit if they:

This is an icon of a heart with ECG strip running through it.

Have uncontrolled hypertension

Consider patients where lifestyle modifications and antihypertensive medications haven’t adequately controlled blood pressure.

This is an icon of a patient lying on a bed in an operating room with a light hanging overhead.

Are willing to undergo an interventional procedure

Consider patients who opt for the Symplicity™ procedure following shared decision-making and an attempt at lifestyle modifications and medical therapy.


Recommended by cardiovascular experts

The 2023 Society for Cardiovascular Angiography and Interventions (SCAI) Position Statement, European Society of Cardiology (ESC) 2024 Guidelines, and the 2024 American Heart Association (AHA) Scientific Statement both recognize renal denervation as a promising therapy for treating hypertension. Read the full statements to learn more.



We‘re here for you at every turn.

Our goal is to support you and your practice as you become familiar with this therapy. We‘ve thought through everything you‘ll need to establish a Symplicity™ renal denervation program and successfully incorporate the procedure into your practice. Our support includes:

  • In-depth training and education
  • Detailed resources for patient selection and education
  • Expert team providing one-on-one support  
This is an image of a male patient sitting near a healthcare professional who is handing him a Medtronic blood pressure brochure.

Sign up for email to stay connected.

We want to provide you with resources that will be the most useful as you acquaint yourself with this procedure.

Sign up so we can send relevant information and resources directly to your inbox.


Find a Symplicity™ proceduralist.

Connect your patients with a proceduralist in your area.

Establish a Symplicity™ RDN program.

See our suggested framework to help create a care pathway.

Products

Filter by

Results may vary across patients.

Includes Symplicity Spyral and Flex catheters.

§ One catheter size treats vessels 3–8 mm.


  1. Centers for Disease Control and Prevention (CDC). Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003-2010. MMWR Morb Mortal Wkly Rep. 2012:61:703–709.
  2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8.
  3. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
  4. Kandzari D, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medication. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
  5. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10234):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.
  6. Mahfound F, Mancia G, Schmieder R, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. EuroPCR 2023.
  7. Medtronic Symplicity Spyral™ multi-electrode renal denervation catheter instructions for use.